It's pretty amazing if you look at Nasrat's career starting with Alpharma and moving forward to Actavis. Pfizer has intellectual property rights on its Embeda and ALO-02 products that were originally owned and worked on while Nasrat was at Alpharma.
King bought Alpharma for those intellectual property rights and Nasrat went to work at King. Alpharma and King got sued by Purdue for patent infringements and King was forced to pay Purdue royalty fees on Embeda. Pfizer comes along and looks at King and Embeda and decided it was worth it to pay those royalty fees to Purdue and buys King anyway. Of course King had solid revenues coming in in addition to Embeda mind you.
Point is Nasrat tells us Elite has superior technology to any that he has seen or worked on.
Elite looks like it is going to launch a whole slew of ART opioids.
Give us a big pharma partner and we are off to the races.
News 
Market Data 
Discover 
AI
